AUS
NZ
UK
CA
USA
IND
Highlights
-
Innovative Drug Development: Roquefort Therapeutics is advancing first-in-class oncology drugs, focusing on high-growth therapeutic areas with the potential for lucrative partnerships.
-
Strategic Partnerships: The company has signed its first out-licensing deal and is actively engaging with major pharmaceutical partners interested in its siRNA programs.
-
Intellectual Property Milestones: Roquefort secured patents for its Mesodermal Killer (MK) cell therapy in Japan and Europe, marking significant advancements in cancer treatment technology.
Description
Roquefort Therapeutics PLC {LSE:ROQ} is a biotechnology company dedicated to developing innovative oncology drugs targeting high-value markets. Since its listing in March 2021, the company has made strategic acquisitions, including Lyramid Pty Limited, which focuses on Midkine—a human growth factor linked to cancer progression—and Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which specializes in advanced cell and RNA oncology therapies.
The company’s portfolio includes four fully funded, patent-protected pre-clinical anti-cancer medicines, showcasing a complementary profile of cutting-edge therapies:
-
Midkine Antibodies: Demonstrating significant in vivo efficacy through extensive toxicology studies.
-
Midkine RNA Therapeutics: Featuring novel anti-cancer gene editing capabilities.
-
MK Cell Therapy: Targeting diseases through direct action and Natural Killer (NK) cell activation.
-
STAT-6 siRNA Therapeutics: Aiming at solid tumors with notable in vivo efficacy.
As of September 27, 2024, Roquefort announced a significant step forward by signing its first out-licensing deal with contract research group PDC, valued initially at $10 million. The CEO, Ajan Reginald, emphasized the importance of selecting novel medicines within lucrative pharmaceutical markets to attract interest from major industry players.
On September 23, 2024, Roquefort obtained a patent for its MK cell therapy in Japan, following similar protections in Europe. This therapy, designed to enhance the body’s immune response against cancer, represents a promising advancement in cancer treatment.
Additionally, recent developments in the company’s STAT-6 siRNA program have shown efficacy in in vitro models of immunological disease. This innovative approach utilizes RNA interference to disrupt gene messaging, targeting critical proteins involved in inflammatory responses.
